GSK1838705A

Catalog No. A11175

GSK1838705A是一种小分子激酶抑制剂,其抑制IGF-IR和胰岛素受体的IC50分别为2.0和1.6 nmol/L。
  • Watanabe S, .et al. Insulin augments serotonin-induced contraction via activation of the IR/PI3K/PDK1 pathway in the rat carotid artery, Pflugers Arch, 2016, Apr;468(4):667-77 PMID: 26577585
Catalog Num A11175
M. Wt 532.57
Formula C27H29FN8O3
Purity >98%
Storage at -20°C 3 years Powder
CAS No. 1116235-97-2
Synonyms GSK-1838705A
SMILES CNC(=O)C1=C(C=CC=C1F)NC2=NC(=NC3=C2C=CN3)NC4=C(C=C5CCN(C5=C4)C(=O)CN(C)C)OC
GSK1838705A是一种小分子激酶抑制剂,其抑制IGF-IR和胰岛素受体的IC50分别为2.0和1.6 nmol/L。
Targets
Target Value
ALKIC50: 0.5nM
Insulin ReceptorIC50: 1.6nM
IGF-1RIC50: 2nM
RSK1IC50: 1.6μM
JNK3IC50: 2μM
B-Raf(V600E)IC50: >2μM
JNK1IC50: 5μM
JAK3IC50: 5μM
JNK2IC50: 8μM
Akt1IC50: >10μM
Akt2IC50: >10μM
ALK5IC50: >10μM
AuroraAIC50: >10μM
AuroraBIC50: >10μM
CaMKK2IC50: >10μM
CDK2/CyclinAIC50: >10μM
EGFRIC50: >10μM
ErbB2IC50: >10μM
HGKIC50: >10μM
IKK3IC50: >10μM
PAK1IC50: >10μM
PCTAIRE1IC50: >10μM
PDK-1IC50: >10μM
PI3KαIC50: >10μM
PI3KβIC50: >10μM
PI3KδIC50: >10μM
PI3KγIC50: >10μM
PKCεIC50: >10μM
ROCK1IC50: >10μM
Src1IC50: >10μM
VEGFR2IC50: >10μM
YAK3IC50: >10μM
p70S6KIC50: >10μM
JAK2IC50: 13μM
JAK1IC50: >25μM
ASK1IC50: >25μM
ErbB4IC50: >25μM
GSK-3βIC50: >25μM
IKK1IC50: >25μM
IKK2IC50: >25μM
ITKIC50: >25μM
LCKIC50: >25μM
MAPKAPK2IC50: >25μM
p38αIC50: >25μM
SykIC50: >25μM
ZAP70IC50: >25μM
In vitro (25°C) DMSO 103 mg/mL (193.4 mM)
Water Insoluble
Ethanol Insoluble
In vivo 15% Captisol+citrate vehicle 28 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 18.78 mL 93.88 mL 187.77 mL
0.5 mM 3.76 mL 18.78 mL 37.55 mL
1 mM 1.88 mL 9.39 mL 18.78 mL
5 mM 0.38 mL 1.88 mL 3.76 mL

*The above data is based on the productmolecular weight 532.57. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.